Since the last review it saw its composite score rise.
Damora Therapeutics, Inc.
DMRA · Nasdaq · USD · Market cap $1.4B · 7 employees
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price23.22 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $40.00 to $45.96, base estimate $45.00 (screen dated 2026-11-20).
- Trend Accumulation
- Insiders insiders bought, latest filing 2026-09-25
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Damora Therapeutics, Inc. holds its Accumulation at $23.22. The statistical read favours the sellers, held for 65 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 65 days |
| Price at the screen | $23.22 |
| Valuation | 13.19 trailing · -10.32 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.51 |
Five Screens: DMRA's Results
FAIL. Accounts receivable
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.03% | Below 33% | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 99.23% | Below 49% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Damora Therapeutics,'s business is fine, but its receivables are about 99% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when DMRA's ethical verdict changes
Today DMRA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 48% discount to our $45.00 fair value.
USD, 2026-11-20 screen. A 48.4% under base.
Street: 9 covering, consensus Strong Buy. Average target +94%.
| Forward P/E | -10.3x |
| Trailing P/E | 13.2xreasonably valued |
| EPS, trailing | 1.71 |
| EPS, forward | -2.19 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -115.8%not currently earning a positive return on equity |
| FCF yield | -1.33% |
| Debt to equity | 0.22minimal debt: a conservative balance sheet |
| Current ratio | 14.80comfortably covers its short-term bills |
| Beta | 1.51much more volatile than the market |
| Short interest, float | 0.09% |
| 52-week range | 15.76 - 38.33 |
| Market cap | $1.4B |
| Employees | 7 |
DMRA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Should Trial Launch Require Action From Damora Therapeutics (DMRA) Investors? Yahoo Finance · 15d ago
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance · 16d ago
- Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Yahoo Finance · 17d ago
- Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting Yahoo Finance · 17d ago
- Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value Yahoo Finance · 10 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Jarrett Jennifer | Dir, Pres, CEO | P - Purchase | 12,500 | $252,875 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $24.36 | -18.4% | · | $816 | -18.4% |
| 2 months | $25.82 | -23.0% | · | $770 | -23.0% |
| 3 months | $26.37 | -24.7% | · | $754 | -24.7% |
| 6 months | $29.01 | -31.5% | · | $685 | -31.5% |
| 1 year | $3.36 | +491.4% | · | $5,914 | +491.4% |
| 2 years | $13.50 | +47.2% | · | $1,472 | +47.2% |
| 3 years | $54.75 | -63.7% | · | $363 | -63.7% |
| 5 years | $140.25 | -85.8% | · | $142 | -85.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever DMRA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.